Skip to content
Screener

EBIT at other companies

Amgen logo
AmgenAMGN
$3.51B+32.3%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.29B+19.8%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-$24.24M-31.7%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-$16.16M-24.0%
Savara logo
SavaraSVRA
-$40.97M-30.3%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$34.64M-25.8%

Other financials

Income statement

See full
Revenue$773.0K-17.5%
Operating income-$42.4M+4.5%
Net income-$39.7M+0.7%
EPS (diluted)-$0.73+1.4%

Balance sheet

See full
Cash & equivalents$79.4M+74.7%
Total debt$954.0K-38.9%
Total equity$271.0M-33.7%
Total assets$281.2M-33.1%

Cash flow

See full
Operating cash flow-$35.6M+9.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$394.54M-54.7%
Enterprise value$316.1M-61.6%
P/S124.9×-195×

Profitability

See full
Operating margin-5,382.6%+1,393pp
Net margin-4,955.7%+2,041pp

Returns & leverage

See full
Return on equity-46%
Debt / equity0.0×
Current ratio28×-10.3×

Where this comes from

Calculated from Upstream Bio, Inc.’s reported figures.

The source filing: Upstream Bio, Inc.’s 10-Q, filed August 11, 2026. Open the filing →

Filed
Aug 11, 2026, 7:10 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-343417

FAQ

What is Upstream Bio, Inc.'s EBIT?
Upstream Bio, Inc. (UPB) reported EBIT of -$42.37M in Q2 2026.
How has Upstream Bio, Inc.'s EBIT changed year-over-year?
Upstream Bio, Inc.'s EBIT increased by 4.5% year-over-year, from -$44.35M to -$42.37M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.

Ask your AI about Upstream Bio, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude